Business Context and Reporting Period
This Form 8-K Current Report for cbdMD, Inc. covers events occurring on February 26, 2023, with the report dated March 2, 2023. The filing primarily addresses the entry into a material definitive agreement for equity financing and significant changes in executive leadership.
Key Financial Metrics and Capital Structure
The filing does not report specific revenue, profit, cash flow, or margin figures for a fiscal period. Instead, it details a new financing facility:
- Financing Facility: A Common Stock Purchase Agreement with Keystone Capital Partners, LLC allowing the sale of up to 12,687,012 shares of common stock over a 12-month period.
- Commitment Shares: 392,382 shares issued immediately as consideration for the commitment (30% issued on signing, with the remainder issued over 90 and 180 days).
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
- Ownership Limits: Sales are capped at 19.99% of outstanding shares (NYSE rule) and 9.99% beneficial ownership for the investor.
Material Changes
Executive Leadership Changes:
- Resignation: Kevin MacDermott resigned as Principal Executive Officer and President effective February 26, 2023. The resignation was not due to any disagreement with the Company.
- Appointment: T. Ronan Kennedy was appointed Interim Chief Executive Officer and Principal Executive Officer on March 1, 2023, resigning from his role as Chief Operating Officer.
Capital Structure: The Company entered into an "at-the-market" equity offering agreement, providing flexibility to raise capital based on market conditions.
Outlook, Risks, and Contingencies
Management Commentary: Management believes the Purchase Agreement provides necessary flexibility to sell common stock subject to market conditions. There are no assurances that the Company will sell shares under the agreement.
Risks and Contingencies:
- Market Conditions: Sales are contingent on the stock price not falling below $0.10 per share for Fixed Purchases.
- Forward-Looking Statements: Actual results may differ materially from anticipated results regarding the completion of sales and proceeds received.
- Termination: The Company may terminate the agreement at any time without cost or penalty (subject to issuing Commitment Shares).
Investor Verification Checklist
- Verify the current trading volume and price of cbdMD common stock (YCBD) to assess the feasibility of the $0.10 price floor for Fixed Purchases.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.1) for specific conditions precedent to the "Commencement Date."
- Monitor subsequent filings for the issuance of the remaining 70% of Commitment Shares.
- Check for any further announcements regarding the permanent appointment of a CEO following the interim appointment of T. Ronan Kennedy.